Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.

Literature DB >> 1628377

A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.

M E O'Brien¹, J Hardy, S Tan, J Walling, B Peters, S Hatty, E Wiltshaw.

Abstract

A total of 16 patients with recurrent epithelial ovarian cancer were treated with sulofenur (LY 186641), a novel oral sulfonylurea. All subjects had received previous chemotherapy. Anaemia occurred in all 16 patients, 14 of whom required a blood transfusion, and 2/16 patients received methylene blue for breathlessness due to methaemaglobinaemia. Treatment was discontinued in 2/16 cases due to rising liver enzyme values, which reverted to normal on cessation of the drug. There was no nausea or alopecia. Only two minor responses were seen. Plasma drug levels were insufficient to result in antitumour activity as extrapolated from animal data. Further studies that attempt to increase the bioavailability and improve the therapeutic index are warranted.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1628377 DOI： 10.1007/bf00686324

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

6 in total

1. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

Authors: M E Gore; I Fryatt; E Wiltshaw; T Dawson
Journal: Gynecol Oncol Date: 1990-02 Impact factor: 5.482

2. Ovarian trials at the Royal Marsden.

Authors: E Wiltshaw
Journal: Cancer Treat Rev Date: 1985-09 Impact factor: 12.111

3. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.

Authors: C W Taylor; D S Alberts; M A Ketcham; W G Satterlee; M T Holdsworth; P M Plezia; Y M Peng; T M McCloskey; D J Roe; M Hamilton
Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544

4. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.

Authors: P J Houghton; J A Houghton; L Myers; P Cheshire; J J Howbert; G B Grindey
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

5. Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea.

Authors: P J Houghton; F C Bailey; G S Germain; G B Grindey; J J Howbert; J A Houghton
Journal: Biochem Pharmacol Date: 1990-04-01 Impact factor: 5.858

6. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

Authors: G Blackledge; F Lawton; C Redman; K Kelly
Journal: Br J Cancer Date: 1989-04 Impact factor: 7.640

6 in total

A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.

1. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

2. Ovarian trials at the Royal Marsden.

3. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.

4. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.

5. Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea.

6. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

1. Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours.

Review 2. Antitumor diarylsulfonylureas: novel agents with unfulfilled promise.

3. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.

4. Phase II trial of LY 186641 in advanced renal cancer.

5. A phase I study of sulofenur in refractory pediatric malignant solid tumors.

Review 6. Glutathione S-conjugates as prodrugs to target drug-resistant tumors.